<DOC>
	<DOCNO>NCT02468661</DOCNO>
	<brief_summary>The purpose study determine maximum tolerate dose ( MTD ) recommend phase II dose ( RP2D ) INC280 combination erlotinib Phase Ib study , assess anti-tumor activity safety INC280 alone , combination erlotinib , versus platinum pemetrexed Phase II study , adult patient EGFR mutate , cMET amplify , advanced/metastatic non-small cell lung cancer acquire resistance prior EGFR TKI .</brief_summary>
	<brief_title>A Safety Efficacy Study INC280 Alone , Combination With Erlotinib , Compared Chemotherapy , Advanced/Metastatic Non-small Cell Lung Cancer Patients With EGFR Mutation cMET Amplification</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Locally advanced metastatic NSCLC EGFR mutation ( L858R /or ex19del ) cMET amplification FISH ( GCN ≥ 6 ) , Acquired resistance EGFR TKI ( 1st 2nd génération ) ECOG performance status ( PS ) ≤ 1 . Prior treatment 3rd generation TKI PhaseII : Prior treatment follow agent : Crizotinib , cMET inhibitor HGFtargeting inhibitor . Concomitant EGFR TKI platinum base chemotherapy first line regimen . Platinumbased chemotherapy first line treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Non-Small Cell Lung Cancer</keyword>
</DOC>